Physician profile
Rehan Memon
NPI 1053433938
$1,700.85
in general payments reported to CMS, 2019-2025
27 companies · $159 in 2025
The $159 reported for 2025 was less than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $431 · 2020: $174 · 2021: $532 · 2022: $222 · 2023: $127 · 2024: $55.78 · 2025: $159.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $341.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $316.10 | 2019-2025 | General - Pain Management |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $290.02 | 2021-2024 | Relistor |
| Medtronic USA, INC. | $258.80 | 2019 | |
| Scilex Pharmaceuticals INC. | $191.68 | 2019-2024 | |
| Medtronic, INC. | $80.22 | 2021-2025 | Intellis Adaptivestim |
| Abbvie INC. | $70.00 | 2025 | |
| Mdd US Operations, LLC | $54.50 | 2020 | |
| Horizon Therapeutics Plc | $52.65 | 2020-2022 | |
| Fujifilm Sonosite, INC. | $41.68 | 2019 | |
| Tersera Therapeutics LLC | $40.78 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $30.04 | 2022 | |
| Forte Bio-Pharma LLC | $26.04 | 2023 | Prolate, Nalocet |
| Pacira Pharmaceuticals Incorporated | $25.77 | 2020 | |
| Hikma Pharmaceuticals USA | $21.00 | 2022 | |
| Smith+Nephew, INC. | $20.28 | 2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19.37 | 2023 | Proclaim |
| Trevena, INC. | $19.31 | 2021 | |
| Uswm, LLC | $17.21 | 2021 | |
| Redhill Biopharma INC. | $17.02 | 2021 | |
| Averitas Pharma INC. | $16.64 | 2025 | Qutenza |
| Biodelivery Sciences International, INC. | $14.89 | 2020 | |
| Baudax Bio INC. | $14.23 | 2021 | |
| Ibsa Pharma INC. | $13.99 | 2021 | |
| Indivior INC. | $13.85 | 2023 | Sublocade |
| Bioventus LLC | $13.43 | 2019 | |
| Pfizer INC. | $10.89 | 2019 | |
| Grt US Holding, INC. | $10.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rehan Memon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.